Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Short-term radiotherapy vs chemoradiotherapy with consolidation chemotherapy and selective organ preservation in MRI-defined intermediate/high-risk rectal cancer
DRKS00020770Phase 3Active, not recruiting
- Sponsor
- Universitätsklinikum Frankfurt
- Start
- Feb 2020
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of oxaliplatin, capecitabine and fluorouracil in rectal cancer (2 arms), sponsored by Universitätsklinikum Frankfurt. Started Feb 2020; status: active, not recruiting.
02
Drugs
oxaliplatincapecitabinefluorouracil
03
Conditions
rectal cancer
Beyond the preview
Go deeper on DRKS00020770.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on DRKS00020770.